Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.

Journal of Breast Cancer, published by the Korean Breast Cancer Society, stands as a pivotal platform for disseminating groundbreaking research and advancements in the field of breast cancer. With an ISSN of 1738-6756 and an E-ISSN of 2092-9900, this open-access journal has been a vital resource since 1998, ensuring that important findings are accessible to all. The journal is situated in South Korea, at 163 Sinmunro 1-ga Jongro-gu, Official Building, Suite 2024, Seoul 110-999, South Korea, fostering an international exchange of knowledge within the scientific community. As a leader in oncology and cancer research, it is categorized in the Q3 quartile for both fields as of 2023, with Scopus rankings reflecting its influence and reach. Researchers and clinicians alike benefit from its rigorous peer-review process and diverse array of articles, which cover the latest studies, treatment strategies, and clinical trials. The Journal of Breast Cancer plays an essential role in shaping future research directions and improving patient outcomes in breast cancer care, making it an invaluable resource for all stakeholders in the oncology field.

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

The International Journal of Breast Cancer is a premier academic platform dedicated to advancing the field of breast cancer research and treatment. Published by HINDAWI LTD, this journal embraces an Open Access model since 2011, ensuring that cutting-edge research is readily accessible to all, facilitating the dissemination of knowledge across the global scientific community. With its ISSN 2090-3170 and E-ISSN 2090-3189, the journal caters to a diverse audience comprising researchers, clinicians, and students engaged in oncology and pharmacology. The journal has consistently demonstrated its relevance, classified in the Q4 quartile for Cancer Research and the Q3 quartile for both Oncology and Pharmacology in the latest rankings. It currently ranks #151/272 in the Medicine & Pharmacology category and #232/404 in Medicine & Oncology according to Scopus, showcasing its adaptive role in an evolving field. Commencing in 2013 and continuing through to 2024, the journal is positioned to be an essential resource, addressing critical topics and fostering innovative solutions for breast cancer challenges.

Breast Care is a prominent academic journal published by KARGER, focusing on the dynamic fields of oncology and surgery. With an ISSN of 1661-3791 and an E-ISSN of 1661-3805, this peer-reviewed journal has established itself as an essential resource for researchers, clinicians, and students dedicated to advancing breast health. Based in Switzerland, it benefits from a strong academic reputation, evident in its impressive Scopus rankings—placing it in the 79th percentile in Surgery (Rank #115/551) and the 53rd percentile in Oncology (Rank #188/404). The journal is recognized for its rigorous exploration of current trends, innovations, and challenges in breast care, encompassing a wide scope from surgical techniques to oncological therapies. With a Q2 ranking in Oncology and a notable Q1 ranking in Surgery as of 2023, Breast Care not only contributes to the advancement of medical knowledge but also fosters interdisciplinary collaboration among healthcare professionals worldwide.

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.